PET Imaging of 68Ga-NOTA-H006 in Malignancy

Launched by YIHUI GUAN · Dec 6, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging agent called 68Ga-NOTA-H006, which helps doctors see certain types of cancer better. The focus is on a protein called 5T4, which is found in high amounts in some cancers, like pancreatic, lung, and bowel cancers. By using this imaging agent, researchers hope to learn more about how it spreads in the body and how it can help in diagnosing these cancers.

To participate in this study, patients must be between 18 and 65 years old and have specific types of cancer, confirmed through imaging or biopsy. They need to be able to give consent and cooperate with the study procedures. Participants will undergo imaging scans to see how the agent works in their bodies. It's important to note that those with severe liver or kidney issues, recent major surgeries, or who are currently part of other trials may not be eligible. This research is still in the early stages, and they are not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Pancreatic cancer clinical trial study subjects must meet all of the following criteria:
• • 1. Age between 18 and 65 years old.
• • 2. Pancreatic occupancy is found on imaging and combined with clinical judgment as a patient with pancreatic cancer.
• • 3. Written informed consent signed by the subject or his/her legal guardian or caregiver.
• • 4. Willingness and ability to cooperate with all programs of the study.
• Lung cancer clinical trial study subjects must meet all of the following criteria:
• • 1. Be between the ages of 18 and 65 years old.
• • 2. Patients with CT findings of suspicious space on the lungs with a diameter of more than 1cm who have not undergone surgery.
• • 3. Written informed consent must be signed by the subject or his/her legal guardian or caregiver.
• • 4. Willingness and ability to cooperate with all programs of the study.
• Bowel cancer clinical trial study subjects must meet all of the following criteria:
• • 1. Be between the ages of 18 and 65.
• • 2. Have a clear histologic or pathologic diagnosis of colorectal cancer.
• • 3. Written informed consent signed by the subject or legal guardian or caregiver.
• • 4. Willingness and ability to cooperate with all programs of this study.
• Exclusion Criteria:
• • 1. Severe hepatic or renal insufficiency;
• • 2. Targeted therapy prior to radiotherapy or PET/CT scan. 5T4 expression in existing lesions assessed by immunohistochemistry using antibody clones.
• • 3. History of serious surgery in the last month.
• • 4. Those who have participated in other clinical trials during the same period.